Impact of kidney bone disease and its management on survival of patients on dialysis.
about
Vitamin D compounds for people with chronic kidney disease not requiring dialysisVitamin D compounds for people with chronic kidney disease requiring dialysisAdministered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysisA multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistencyKidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI)Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures.Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.HCV genotype-specific correlation with serum markers: higher predictability for genotype 4aVitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.Association of laboratory parameters with viral factors in patients with hepatitis C.Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients.VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.Ferric citrate (auryxia) for the treatment of hyperphosphatemia.Chronic kidney disease and its complications.Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients.25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcificationPotential for vitamin D receptor agonists in the treatment of cardiovascular disease.Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease.Associations of serum alkaline phosphatase with metabolic syndrome and mortality.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Vitamin D receptor activation and cardiovascular disease.Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.Vitamin D in chronic kidney disease: is the jury in?Two novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats.Vitamin D deficiency, insulin resistance, and ventricular hypertrophy in the early stages of chronic kidney disease.Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials.The vitamin D system: a crosstalk between the heart and kidney.Evaluation of the Relationship between the Serum Alkaline Phosphatase Level at Dialysis Initiation and All-Cause Mortality: A Multicenter, Prospective Study.Alkaline phosphatase: Better than PTH as a marker of cardiovascular and bone disease?
P2860
Q24240439-D3F8D26C-7077-43CB-99EC-8AA078822004Q24240582-6C2F4BB5-6196-402D-A08C-38ECEC5C7089Q30408489-0F199C3D-70E3-44CB-BCAA-9AE9201EF38FQ30430605-94F7CE50-B10F-40BD-A6DD-1979F33FCCC6Q33862710-25FCAC21-76A4-4186-AE05-62C012F79B1DQ33877980-36F93CC1-A4CD-4718-91B1-97B9600424C7Q33932610-81A8F96C-8F77-43A5-9ED3-065ECAA624E0Q34610602-2C182768-36A1-4AE8-BCE4-9EC848DBBCF7Q35068407-05C70201-63E5-4BC5-900E-943C3B2762EEQ35086461-CC4E2BDC-B19F-4F21-89A8-635B65D7F91AQ35158444-B1A5E0CD-4FD2-4E59-A649-A5DFEB97E4A9Q35229831-3507E4B4-9925-417E-85B9-E3F47EA2D87CQ35287391-0B88BEFD-8ECC-4FAB-998E-B29AB2337CEBQ35577405-6D75A647-C2BC-487D-A11B-1421FA148BCDQ36776175-E348BBE6-B503-4F92-83F0-2CAB8510CBACQ36947319-D4235AE1-2BB6-4826-A216-9250E91AB1EFQ36949233-437B754F-0963-4371-BBE7-2281D5195E62Q37035402-48A0E9E8-1946-421F-9CA2-6C1CCE583B5CQ37297677-26C47AD9-B8CB-4989-8262-CC47526B670BQ37376932-2D635F56-F1A3-47D6-95E4-30770BDF3EABQ37415703-7990F6B7-638B-49CE-AD6D-4EAA8D3037A6Q37603149-8B3D43B4-7B66-46AB-8805-0B3E51CB8381Q37891153-1A9FA505-8C00-4E48-A52A-15C5FE1CA055Q38069143-5EA568FD-1B9B-4D91-9B60-4D84C5C7AA8DQ38436799-DDBAA257-5638-4CD3-B9BA-5EF413EB4CFAQ41850703-6545FEB5-2EDE-4F23-B1BF-D7A63D4D2451Q43658115-B1D0ACD8-504C-42AF-9C4E-563E585F7A0FQ44981409-7244E39D-8D45-488C-AE66-D04AD4E6F18EQ48283940-54E30F55-B7ED-4DDF-B33E-D6F53AFB7082Q53314344-E70B6499-FE62-4D95-85DA-098EC87D2D83Q55055749-3C2C1F05-4F9A-47F8-976A-AE3A1078756EQ57771661-0BF12069-5FBF-4A0F-80CD-CBFB9C0EEF01
P2860
Impact of kidney bone disease and its management on survival of patients on dialysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Impact of kidney bone disease and its management on survival of patients on dialysis.
@ast
Impact of kidney bone disease and its management on survival of patients on dialysis.
@en
type
label
Impact of kidney bone disease and its management on survival of patients on dialysis.
@ast
Impact of kidney bone disease and its management on survival of patients on dialysis.
@en
prefLabel
Impact of kidney bone disease and its management on survival of patients on dialysis.
@ast
Impact of kidney bone disease and its management on survival of patients on dialysis.
@en
P2093
P1476
Impact of kidney bone disease and its management on survival of patients on dialysis.
@en
P2093
Deborah Benner
Deborah L Regidor
Grace H Lee
P356
10.1053/J.JRN.2006.07.006
P577
2007-01-01T00:00:00Z